MedTrace Logo

To Evaluate SSD8432/ Ritonavir in Adults With COVID-19

NCT05369676 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-05-31

No results posted yet for this study

Summary

This is a randomized, double-blind, Phase 1b clinical trial to evaluate the safety, Pharmacodynamics, and Pharmacokinetic of SSD8432 combined with ritonavir tablets in adults with COVID-19.

Conditions

  • COVID-19 Patients

Interventions

DRUG

SSD8432 dose 1/Ritonavir

Cohort 1:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；

DRUG

SSD8432 dose 2/Ritonavir

Cohort 2:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；

Sponsors & Collaborators

  • Jiangsu Simcere Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yumei Yang · Jiangsu Xiansheng Pharmaceutical Co., LTD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-12
Primary Completion
2022-08-29
Completion
2022-08-29

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05369676 on ClinicalTrials.gov